Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Lemery

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Journal of Oncology Practice|September 13, 2017
When One Is a Hammer, Everything Looks Like a NailSteven J Lemery
Cancer Discovery|September 4, 2021
Tissue-Agnostic Drug Development: A New Path to Drug ApprovalKyaw Z Thein, Steven J Lemery, Shivaani Kummar
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Biosimilars: Here and NowSteven J Lemery, Francisco J Esteva, Martina Weise
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2019
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Steven J Lemery, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2016
FDA's Approach to Regulating BiosimilarsSteven J Lemery, M Stacey Ricci, Patricia Keegan, et al.
The Oncologist|January 8, 2011
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemiaSandra J Casak, Steven J Lemery, Yuan Li Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric CancerSandra J Casak, Yiming Zhang, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumabSteven J Lemery, Jenny Zhang, Mark D Rothmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2022
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic DiseaseM Naomi Horiba, Sandra J Casak, Pallavi S Mishra-Kalyani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2023
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular CarcinomaTimil H Patel, Jamie R Brewer, Jiaxin Fan, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Journal of Oncology Practice|September 13, 2017
When One Is a Hammer, Everything Looks Like a NailSteven J Lemery
Cancer Discovery|September 4, 2021
Tissue-Agnostic Drug Development: A New Path to Drug ApprovalKyaw Z Thein, Steven J Lemery, Shivaani Kummar
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Biosimilars: Here and NowSteven J Lemery, Francisco J Esteva, Martina Weise
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2019
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Steven J Lemery, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2016
FDA's Approach to Regulating BiosimilarsSteven J Lemery, M Stacey Ricci, Patricia Keegan, et al.
The Oncologist|January 8, 2011
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemiaSandra J Casak, Steven J Lemery, Yuan Li Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric CancerSandra J Casak, Yiming Zhang, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumabSteven J Lemery, Jenny Zhang, Mark D Rothmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2022
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic DiseaseM Naomi Horiba, Sandra J Casak, Pallavi S Mishra-Kalyani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2023
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular CarcinomaTimil H Patel, Jamie R Brewer, Jiaxin Fan, et al.
Pageof 4